Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Eisai China to Repack and Sell STADA Diabetes Drug

publication date: Aug 4, 2008

Eisai China, Inc. (ECI), the wholly owned China subsidiary of Japan pharma Eisai Co., will repack and sell Alpha-Lipon 300 STADA®, an alpha-lipoic acid. Alpha-Lipon 300 STADA is a treatment for diabetic neuropathic pain developed by STADA Arzneimittel AG and currently sold through the company’s sales subsidiary Health Vision Enterprise Ltd. Available in China since 2005, Alpha-Lipon 300 STADA treats diabetic neuropathic pain through an antioxidant effect, which reduces overproduction of oxygen and normalizes glucose metabolism. More details... 



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here